ATE273384T1 - Tie-2 liganden, herstellungsverfahren und verwendung - Google Patents

Tie-2 liganden, herstellungsverfahren und verwendung

Info

Publication number
ATE273384T1
ATE273384T1 AT96910769T AT96910769T ATE273384T1 AT E273384 T1 ATE273384 T1 AT E273384T1 AT 96910769 T AT96910769 T AT 96910769T AT 96910769 T AT96910769 T AT 96910769T AT E273384 T1 ATE273384 T1 AT E273384T1
Authority
AT
Austria
Prior art keywords
tie
provides
human
growth
ligand
Prior art date
Application number
AT96910769T
Other languages
English (en)
Inventor
Samuel Davis
Joanne Bruno
Mitchell Goldfarb
Thomas H Aldrich
Peter C Maisonpierre
Czeslaw Radziejewski
Pamela F Jones
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/418,595 external-priority patent/US5814464A/en
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE273384T1 publication Critical patent/ATE273384T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96910769T 1995-04-06 1996-04-05 Tie-2 liganden, herstellungsverfahren und verwendung ATE273384T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/418,595 US5814464A (en) 1994-10-07 1995-04-06 Nucleic acids encoding TIE-2 ligand-2
PCT/US1995/012935 WO1996011269A2 (en) 1994-10-07 1995-10-06 Tie-2 ligands, methods of making and uses thereof
PCT/US1996/004806 WO1996031598A1 (en) 1995-04-06 1996-04-05 Tie-2 ligands, methods of making and uses thereof

Publications (1)

Publication Number Publication Date
ATE273384T1 true ATE273384T1 (de) 2004-08-15

Family

ID=23658779

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96910769T ATE273384T1 (de) 1995-04-06 1996-04-05 Tie-2 liganden, herstellungsverfahren und verwendung

Country Status (9)

Country Link
US (1) US6627415B1 (de)
EP (1) EP0821728B1 (de)
JP (1) JP4122056B2 (de)
AT (1) ATE273384T1 (de)
AU (1) AU715621B2 (de)
CA (1) CA2216963C (de)
DE (1) DE69633121T2 (de)
HK (1) HK1008230A1 (de)
WO (1) WO1996031598A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846914B2 (en) 1996-06-19 2005-01-25 Regeneron Pharmaceuticals, Inc. Tie-2 ligand-3
EP0939809B1 (de) * 1996-06-19 2003-03-26 Regeneron Pharmaceuticals, Inc. Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
US6265564B1 (en) * 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US6057435A (en) * 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6350450B1 (en) 1997-09-19 2002-02-26 Genentech, Inc. TIE ligand homologue antibody
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999062925A1 (en) * 1998-06-02 1999-12-09 Eli Lilly And Company Angiopoietin related gene sequence scarface 1
SV1999000069A (es) * 1998-06-02 2000-04-11 Lilly Co Eli Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
WO1999067382A2 (en) * 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
EP1117765A2 (de) * 1998-08-31 2001-07-25 New York University Stammzellen mit einem fgf rezeptor auf der zelloberfläche
EP1141294B1 (de) 1998-12-23 2005-03-02 Regeneron Pharmaceuticals, Inc. Methode zur verstärkung der biologischen aktivität von liganden
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
AU783960B2 (en) 1999-06-07 2006-01-05 Immunex Corporation Tek antagonists
EP1330544A4 (de) * 2000-09-26 2005-04-06 Univ Duke Rna-aptamere und verfahren zu deren identifizierung
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7052695B2 (en) 2001-10-25 2006-05-30 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of treating hypertension
JP4242590B2 (ja) * 2002-01-11 2009-03-25 俊一 塩澤 慢性関節リウマチの疾患感受性遺伝子、及びその利用
US7427594B1 (en) * 2002-02-26 2008-09-23 The Trustees Of The University Of Pennsylvania Methods and pharmaceuticals compositions for treating coronary artery disease, ischemia,and vascular disease using angiopoietins
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
WO2004045531A2 (en) 2002-11-14 2004-06-03 Cornell Research Foundation, Inc. Protection of cardiac myocardium
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
WO2005019267A2 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
EP2457578B1 (de) 2004-09-28 2015-08-19 Aprogen, Inc. Chimärisches Molekul enthaltend Angiopoietin-1 und einen Coiled-Coil Domäne zur Behandlung der erektylen disfunktion des Penis
WO2006068953A2 (en) 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
US20080213253A1 (en) * 2007-01-12 2008-09-04 Dyax Corp. Combination therapy for the treatment of cancer
JP5596559B2 (ja) 2008-01-28 2014-09-24 メディミューン リミテッド 安定化アンジオポエチン２抗体とその用途
EP2671891A3 (de) 2008-06-27 2014-03-05 Amgen Inc. Ang-2-Hemmung zur Behandlung von Multipler Sklerose
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
MX371382B (es) 2013-03-15 2020-01-28 Aerpio Therapeutics Inc Composiciones, formulaciones y metodos para tratar enfermedades oculares.
WO2014144600A2 (en) 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
JP6483148B2 (ja) 2014-03-14 2019-03-13 エアーピオ セラピューティクス インコーポレイテッド ＨＰＴＰ−β阻害剤
US10670611B2 (en) 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0550296A3 (en) 1991-11-28 1993-12-29 Terumo Corp Vascular endothelial cells growth factor
US5955291A (en) 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
WO1994000469A1 (en) * 1992-06-26 1994-01-06 Immunex Corporation Novel tyrosine kinase
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2

Also Published As

Publication number Publication date
DE69633121T2 (de) 2005-07-28
DE69633121D1 (de) 2004-09-16
EP0821728B1 (de) 2004-08-11
JPH11503323A (ja) 1999-03-26
WO1996031598A1 (en) 1996-10-10
AU715621B2 (en) 2000-02-03
JP4122056B2 (ja) 2008-07-23
AU5387196A (en) 1996-10-23
CA2216963C (en) 2010-06-22
HK1008230A1 (en) 1999-05-07
EP0821728A1 (de) 1998-02-04
US6627415B1 (en) 2003-09-30
CA2216963A1 (en) 1996-10-10
EP0821728A4 (de) 1998-08-19

Similar Documents

Publication Publication Date Title
ATE273384T1 (de) Tie-2 liganden, herstellungsverfahren und verwendung
FI971406A (fi) TIE-2-ligandeja ja menetelmiä niiden valmistamiseksi ja käyttämiseksi
Tentori et al. Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3.
DE122008000030I1 (de) Therapeutische Zusammensetzungen die monoklonale Antikörper enthalten gegen den menschlichen Rezeptor für epidermalen Wachstumsfaktor
ATE354372T1 (de) Verwendung von mif-antagonisten zur krebstherapie
FI982745A (fi) TIE-2-reseptoriligandit (TIE-ligandi-3; TIE-ligandi-4) ja niiden käytt"
US20040202664A1 (en) Prevention of tumors with monoclonal antibodies against neu
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
DE69839209D1 (de) Cathepsin K und Brustkrebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0821728

Country of ref document: EP